Background: Worldwide, the use of prostate specific antigen (PSA) testing as a screen for prostate cancer is contentious. Whilst there is no National UK Screening programme, many men undergo opportunistic screening. This study investigates UK urologist's usage of PSA and the awareness surrounding the Department of Health (DoH) PSA guidelines.
Methods: Urologists were sent a questionnaire regarding PSA cut-off values.
Results: Of the 733 urologists eligible to participate in this study 346 returned completed questionnaires giving a response rate of 47%. The most commonly generally used age-related PSA cut-off values (36% of respondents) are--3.5 ng/ml for 50 - 59 year olds, 4.5 ng/ml for 60 - 69 year olds and 6.5 ng/ml for over 70 year olds. Two-thirds (58%, 200/346) of respondents were aware of the DoH PSA guidelines but only 20% (n = 69/346) follow these guidelines. The majority of respondents (68%, n = 234/346) used higher PSA cut-offs than recommended by the DoH. The level of compliance showed marked regional variation with a range from 7% to 44% (median 19%). In addition, it was apparent that lower PSA cut-off values were used in private practice as opposed to the National Health Service.
Conclusion: A nationwide lack of agreement on PSA cut-off values may generate a variable standard of care both regionally and in NHS versus private practice. Generally, higher PSA cut-off values are being used than recommended by the DoH guidance.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2606676 | PMC |
| http://dx.doi.org/10.1186/1471-2490-8-17 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Role of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in predicting carcinoma prostate (CaP) in patients with lower urinary tract symptoms and raised serum prostate-specific antigen (sr.PSA).
Med J Armed Forces India
December 2024
Professor & Head (Urology), Bharati Vidyapeeth (Deemed to be University), Pune, India.
Background: Carcinoma prostate (CaP) is second most common cancer and sixth leading cause of cancer-related mortality among men worldwide. Prostate-specific antigen (sr. PSA) levels are prostate specific, not cancer specific.
View Article and Find Full Text PDFC-reactive protein thresholds for discriminating active disease in psoriatic arthritis may be different in early versus established disease.
Clin Exp Rheumatol
December 2024
Rheumatology Division, Central University Hospital of Asturias, Oviedo; Department of Medicine, Oviedo University School of Medicine, Oviedo; and Translational Immunology Division, Biohealth Research Institute of the Principality of Asturias (ISPA), Oviedo, Spain.
Objectives: Inflammatory biomarkers such as C-reactive protein (CRP) lack discriminatory capacity to detect active disease in psoriatic arthritis (PsA). Our aim was to find CRP thresholds capable of discriminating active disease in both early and established PsA.
Methods: We included a total of 345 PsA patients (215 early-onset not exposed to high-impact therapies and 130 with established disease under biologics and oral targeted therapies).
Development and external validation of a prediction model for the risk of relapse in psoriasis after discontinuation of biologics.
Front Med (Lausanne)
November 2024
Department of Dermatology, China-Japan Friendship Hospital, National Center for Integrative Chinese and Western Medicine, Beijing, China.
Background: Some patients with psoriasis experience relapses shortly after discontinuation of biologics. However, there is a lack of risk prediction tools to identify those at high risk of relapse.
Objective: To develop and validate a risk prediction model for psoriasis relapse after biologics discontinuation.
Racial Disparities in Future Development of Lethal Prostate Cancer Based on Midlife Baseline Prostate-Specific Antigen.
Prostate
December 2024
VUI Center for Outcomes Research, Analysis, and Evaluation, Henry Ford Health System, Detroit, Michigan, USA.
Background: Previous studies found that Midlife Baseline PSA (MB PSA) predicts the risk of developing lethal prostate cancer (PCa), although the cohorts were homogenous in terms of racial compositions. We aimed to investigate racial disparities in the predictive value of MB PSA for lethal PCa in a diverse, contemporary, North American population.
Methods: Our cohort included White and Black men aged 40-59 years, who underwent MB PSA through our health system.
Development and validation of a nomogram prediction model for clinically significant prostate cancer combined with PI-RADS V2.1, MRI quantitative parameters and clinical indicators: a two-center study.
Front Oncol
November 2024
Medical Imaging Department, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Article Synopsis
- A multi-index nomogram prediction model was developed to assess clinically significant prostate cancer by integrating PI-RADS V2.1 scores, quantitative MRI parameters, and clinical factors in a study involving over 2000 patients.
- The model's effectiveness was evaluated using various statistical methods, including AUC (Area Under the Curve), revealing high sensitivity and specificity, particularly with two models: one combining PI-RADS and PSAD, and another that added ADCmean.
- Validation results indicated strong performance in predicting CSPCa across both internal and external cohorts, with no significant difference found between predicted and actual probabilities, supporting the model's reliability.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!